- Home
- ACT vs GPCR Comparison
ACT vs GPCR Comparison
Compare ACT & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ACT | GPCR |
|---|---|---|
| Founded | 1981 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.3B |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ACT | GPCR |
|---|---|---|
| Price | $40.27 | $46.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $42.67 | ★ $103.36 |
| AVG Volume (30 Days) | 261.1K | ★ 870.4K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.06% | N/A |
| EPS Growth | ★ 3.43 | N/A |
| EPS | ★ 4.52 | N/A |
| Revenue | ★ $1,235,827,000.00 | N/A |
| Revenue This Year | $4.22 | N/A |
| Revenue Next Year | $2.33 | N/A |
| P/E Ratio | $9.02 | ★ N/A |
| Revenue Growth | ★ 2.83 | N/A |
| 52 Week Low | $31.28 | $13.24 |
| 52 Week High | $44.80 | $94.90 |
Technical Indicators
Market Signals| Indicator | ACT | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 42.47 | 26.76 |
| Support Level | $39.31 | $18.36 |
| Resistance Level | $41.12 | $61.20 |
| Average True Range (ATR) | 0.81 | 3.05 |
| MACD | -0.06 | -0.31 |
| Stochastic Oscillator | 17.22 | 9.86 |
Price Performance
Historical ComparisonAbout ACT Enact Holdings Inc.
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The company operates in a single reportable segment namely Mortgage Insurance The principal mortgage insurance customers are originators of residential mortgage loans that determines the mortgage insurer or insurers to be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.